Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 8/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL553857 | 0.89 | EPHA2 (0.45) | PDK1NR1H4EPHA2SMN1; SMN2 | |
| SCHEMBL553856 | 0.89 | EPHA2 (0.45) | PDK1NR1H4EPHA2SMN1; SMN2 | |
| SCHEMBL31299431 | 0.84 | SMYD2 (0.38) | PDK1SMYD2SMN1; SMN2PSEN1PSEN2 | |
| SCHEMBL29080094 | 0.83 | SMYD2 (0.39) | PDK1SMYD2SMN1; SMN2PSEN1PSEN2 | |
| SCHEMBL29080085 | 0.82 | SMYD2 (0.39) | SMYD2SMN1; SMN2 | |
| SCHEMBL17065348 | 0.82 | SMYD2 (0.38) | SMYD2SMN1; SMN2PSEN1PSEN2APH1B | |
| SCHEMBL19181577 | 0.81 | SMYD2 (0.37) | SMYD2SMN1; SMN2PSEN1PSEN2APH1B | |
| SCHEMBL15414558 | 0.80 | PDK1 (0.45) | PDK1HRH3EPHA2 | |
| SCHEMBL29211546 | 0.80 | RBP4 (0.46) | SMYD2 | |
| SCHEMBL19181556 | 0.80 | SMYD2 (0.37) | SMYD2SMN1; SMN2PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| EP-2601177-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| WO-2012017251-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | PDK1 347/4885HRH3 4662/4885SMYD2 2749/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | PDK1 347/4885HRH3 4662/4885SMYD2 2749/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | PDK1 347/4885HRH3 4662/4885SMYD2 2749/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | PDK1 1635/4885HRH3 4620/4885SMYD2 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.